NewsDesk @bactiman63 Evidence of human-to-dog transmission of monkeypox virus Published in The Lancet this week, researchers from France describe a human-to-dog monkeypox transmission. 12 days after symptom...

NewsDesk @bactiman63 Pfizer Inc. and Valneva SE announced the initiation of a Phase 3 clinical study, Vaccine Against Lyme for Outdoor Recreationists (VALOR) (NCT05477524), to investigate the efficacy,...

By

NewsDesk @bactiman63 During sentinel surveillance of febrile patients with a recent history of animal exposure in eastern China, a phylogenetically distinct henipavirus, named Langya henipavirus (LayV),...

NewsDesk @bactiman63 Researchers from the University of Oxford have recently reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single...

NewsDesk @bactiman63 One in eight adults (12.7%) who are infected with SARS-CoV-2 experience long term symptoms due to COVID-19, suggests a large Dutch study published in The Lancet. The study provides...

NewsDesk @bactiman63 Lyme disease has become an illness of increasing national concern in the United States. From 2007 to 2021, private insurance claim lines with Lyme disease diagnoses rose 357 percent...

NewsDesk @bactiman63 Recent acute hepatitis cases of unknown origin in children have now been linked to the virus AAV2 in two new UK studies, with no evidence of a direct link to SARS-CoV-2 infection. Submitted...

NewsDesk @bactiman63 A case series which is the result of an international collaboration across 16 countries is published on 21 July 2022 in The New England Journal of Medicine (NEJM). The study, led...

NewsDesk @bactiman63 Bacteria causing Typhoid fever are becoming increasingly resistant to some of the most important antibiotics for human health, according to a study published in The Lancet Microbe...

NewsDesk @bactiman63 Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and when it might...